Opendata, web and dolomites

TICARDIO SIGNED

Thrombo-inflammation in cardiovascular disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TICARDIO project word cloud

Explore the words cloud of the TICARDIO project. It provides you a very rough idea of what is the project "TICARDIO" about.

minded    setting    age    mechanisms    structures    unmet    linkages    small    pharmaceutical    germany    diverse    omics    centres    ticardio    mechanistic    dissect    independently    interconnected    care    multifaceted    careers    cvd    netherlands    formed    alliance    thrombo    biomedical    train    patient    becomes    complications    successful    fosters    vasculature    company    completion    entrepreneurial    atherosclerosis    vascular    heavy    generation    health    translational    integration    stroke    drivers    risk    provides    independent    settings    disarrayed    killers    creative    companies    places    inflammation    worldwide    france    multicellular    disease    knowledgeable    environment    competitive    myocardial    interactions    medical    benefit    blueprint    area    thrombosis    strategic    types    cardiovascular    infarction    finely    serve    business    academic    technologies    populations    central    outstanding    exposing    tuned    despite    pathological    training    multidisciplinary    interplay    burden    cell    unravel    translate    beneficiaries    complementary    aging    demographic    broadly    medicine    basic   

Project "TICARDIO" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ 

Organization address
address: Langenbeckstrasse 1
city: Mainz
postcode: 55131
website: http://www.um-mainz.de/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙944˙037 €
 EC max contribution 3˙944˙037 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-EJD
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2023-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ DE (Mainz) coordinator 1˙263˙942.00
2    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 1˙328˙099.00
3    UNIVERSITE D'AIX MARSEILLE FR (Marseille) participant 1˙099˙208.00
4    LEIBNIZ-INSTITUT FUR ANALYTISCHE WISSENSCHAFTEN-ISAS-EV DE (DORTMUND) participant 252˙788.00
5    2M ENGINEERING LIMITED UK (FOLKSTONE) partner 0.00
6    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) partner 0.00
7    Biocytex FR (MARSEILLE) partner 0.00
8    BOEHRINGER INGELHEIM PHARMA GMBH &CO KG DE (INGELHEIM) partner 0.00
9    TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH DE (MAINZ) partner 0.00
10    TTOPSTART BV NL (UTRECHT) partner 0.00

Map

 Project objective

The demographic change with aging populations places a heavy burden on health care systems worldwide. Despite all medical advances, age remains the major risk for cardiovascular disease (CVD), one of the top two killers. The aging vasculature provides an environment in which the finely tuned interplay between diverse cell types becomes disarrayed and thus fosters both, inflammation and thrombosis. For atherosclerosis and major vascular complications, i.e. myocardial infarction and stroke, inflammation and thrombosis are central pathological processes that have commonly been investigated independently, but now need integration within the new concept of 'vascular thrombo-inflammation'. Four beneficiaries have formed a strategic alliance to unravel the multifaceted mechanisms involved in thrombo-inflammation in the setting of CVD and identified interconnected research projects that benefit from the collaboration between outstanding centres in France, Germany and The Netherlands. Using unique and complementary advanced technologies, TICARDIO will dissect the mechanistic linkages between inflammation and thrombosis, investigate the multicellular interactions in the vasculature as drivers for thrombo-inflammation, and translate new concepts by multi-omics approaches into patient populations. The programme will train the next generation of basic and translational researchers by exposing them to a multidisciplinary research environment at major academic centres and a range of entrepreneurial and business settings at small and large pharmaceutical companies in Europe. The completion of an independent project in a research area with high unmet medical need will foster the development of creative, open minded and broadly knowledgeable biomedical researchers who are competitive for successful academic and company careers all over Europe. TICARDIO’s structures and interactions will serve as a blueprint for future training programmes in emerging fields of cardiovascular medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TICARDIO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TICARDIO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

DELIVER (2019)

DELIVERy of advanced therapies for diabetes training network

Read More